Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Patrick R. O’neil Sells 6,165 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Patrick R. O’neil sold 6,165 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total transaction of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares in the company, valued at $1,816,632.24. This represents a 9.69 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Ionis Pharmaceuticals Stock Performance

NASDAQ IONS opened at $31.40 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The firm has a market capitalization of $4.96 billion, a price-to-earnings ratio of -12.87 and a beta of 0.35. The company’s fifty day moving average is $34.88 and its two-hundred day moving average is $39.79. Ionis Pharmaceuticals, Inc. has a 52-week low of $31.03 and a 52-week high of $52.34.

Institutional Trading of Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nicollet Investment Management Inc. grew its position in Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock worth $817,000 after purchasing an additional 294 shares during the last quarter. Amalgamated Bank boosted its position in shares of Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after acquiring an additional 300 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after acquiring an additional 303 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in shares of Ionis Pharmaceuticals by 40.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after acquiring an additional 314 shares in the last quarter. Finally, Bleakley Financial Group LLC boosted its position in shares of Ionis Pharmaceuticals by 2.1% during the 3rd quarter. Bleakley Financial Group LLC now owns 16,678 shares of the company’s stock valued at $668,000 after acquiring an additional 338 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IONS has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Royal Bank of Canada restated an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. Wells Fargo & Company cut their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Piper Sandler cut their price target on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.